Jane Huang Sells 1,100 Shares of Beigene Ltd (BGNE) Stock
Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,100 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.00, for a total transaction of $94,600.00. Following the transaction, the chief marketing officer now owns 264,900 shares in the company, valued at $22,781,400. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Jane Huang also recently made the following trade(s):
- On Thursday, November 16th, Jane Huang sold 600 shares of Beigene stock. The shares were sold at an average price of $85.00, for a total transaction of $51,000.00.
- On Monday, November 20th, Jane Huang sold 1,600 shares of Beigene stock. The shares were sold at an average price of $86.25, for a total transaction of $138,000.00.
Beigene Ltd (NASDAQ BGNE) traded up $13.50 during mid-day trading on Tuesday, hitting $94.50. 1,747,800 shares of the company were exchanged, compared to its average volume of 203,371. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33. Beigene Ltd has a 1-year low of $26.43 and a 1-year high of $118.95.
BGNE has been the topic of a number of research analyst reports. Ladenburg Thalmann Financial Services initiated coverage on shares of Beigene in a research note on Monday, August 7th. They set a “buy” rating and a $81.00 price objective on the stock. Zacks Investment Research downgraded shares of Beigene from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Goldman Sachs Group reissued a “buy” rating and set a $86.00 target price (up from $43.00) on shares of Beigene in a report on Tuesday, August 15th. Maxim Group reissued a “buy” rating and set a $77.00 target price on shares of Beigene in a report on Monday, September 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $95.00 target price (up from $87.00) on shares of Beigene in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $96.67.
Several hedge funds have recently added to or reduced their stakes in the stock. Hillhouse Capital Management Ltd. grew its position in Beigene by 172.6% in the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after buying an additional 2,355,906 shares in the last quarter. Orbimed Advisors LLC grew its position in Beigene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock valued at $135,925,000 after buying an additional 26,200 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Beigene in the 3rd quarter valued at about $62,076,000. Artal Group S.A. grew its position in Beigene by 10.1% in the 2nd quarter. Artal Group S.A. now owns 400,000 shares of the company’s stock valued at $18,000,000 after buying an additional 36,714 shares in the last quarter. Finally, Myriad Asset Management Ltd. grew its position in Beigene by 16.6% in the 2nd quarter. Myriad Asset Management Ltd. now owns 385,585 shares of the company’s stock valued at $17,351,000 after buying an additional 54,900 shares in the last quarter. 55.34% of the stock is currently owned by institutional investors and hedge funds.
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.